Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Targeted Covalent Pentafluorobenzene Sulfonamide-Based Afatinib Drug for Treating Breast Cancer

FY 2019-20

Summary
"Breast cancer is a common malignancy in Canadian women accounting for approximately 14 deaths daily. Although there have been several advancements in treatments, current drugs are plagued by resistance mechanisms and off-target effects which leads to higher dosing regimens and unpleasant side effects. This is particularly important for a class of drugs, termed covalent therapeutics. Covalent therapeutics, unlike conventional drugs, are very reactive molecules and bind irreversibly to their target which halts its normal function. Although this is a desirable objective in a cancer cell, since covalent therapeutics are very reactive, they can also bind irreversibly to non-cancer targets, which contributes to patient side-effects and toxicity. We have recently developed new technology that allows us to fine-tune the reactivity of a covalent therapeutic thereby limiting off target effects. We are aiming to apply this technology to current breast cancer treatments, such as the current breast-cancer drug afatinib. We will synthesize a large library of afatinib-like drugs based on our new technology. We will use state-of-the-art computer simulations and quantum mechanical models, to predict the reactivity of the different compounds. We will test these compounds against breast-cancer cells in an isolated petri dish to determine their potency and effectiveness. In this strategy, we will gradually funnel our large library of compounds to generate a small number of the top hits with convincing drug profiles. Since afatinib is currently dosed with other drug combinations for breast cancer, we hope this research seeks to find a treatment that not only improve the quality of life for Canadian women but also extend the life span of women diagnosed with breast cancer."
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428860
Name
Hekmat Merna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeted Covalent Pentafluorobenzene Sulfonamide-Based Afatinib Drug for Treating Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Afatinib Drug; Biophysical Assay; Breast Cancer; Covalent Inhibitors; Drug Discovery; Electrophilic Tuning; Epidermal Growth Factor Receptor; Kinases; Nucleophilic Aromatic Substitution; Pentafluorobenzene Sulfonamide
Abstract
"Breast cancer is a common malignancy in Canadian women accounting for approximately 14 deaths daily. Although there have been several advancements in treatments, current drugs are plagued by resistance mechanisms and off-target effects which leads to higher dosing regimens and unpleasant side effects. This is particularly important for a class of drugs, termed covalent therapeutics. Covalent therapeutics, unlike conventional drugs, are very reactive molecules and bind irreversibly to their target which halts its normal function. Although this is a desirable objective in a cancer cell, since covalent therapeutics are very reactive, they can also bind irreversibly to non-cancer targets, which contributes to patient side-effects and toxicity. We have recently developed new technology that allows us to fine-tune the reactivity of a covalent therapeutic thereby limiting off target effects. We are aiming to apply this technology to current breast cancer treatments, such as the current breast-cancer drug afatinib. We will synthesize a large library of afatinib-like drugs based on our new technology. We will use state-of-the-art computer simulations and quantum mechanical models, to predict the reactivity of the different compounds. We will test these compounds against breast-cancer cells in an isolated petri dish to determine their potency and effectiveness. In this strategy, we will gradually funnel our large library of compounds to generate a small number of the top hits with convincing drug profiles. Since afatinib is currently dosed with other drug combinations for breast cancer, we hope this research seeks to find a treatment that not only improve the quality of life for Canadian women but also extend the life span of women diagnosed with breast cancer."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hekmat, Merna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~